

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 87300035.0

(51) Int. Cl.³: **A 61 K 9/22**
A 61 K 47/00

(22) Date of filing: 06.01.87

(30) Priority: 18.01.86 GB 8601204

(43) Date of publication of application:
02.09.87 Bulletin 87/36

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: **THE BOOTS COMPANY PLC**
1 Thane Road West
Nottingham NG2 3AA(GB)

(72) Inventor: **Pankhania, Mahendra Govind**
20 Queens Road East
Beeston Nottingham(GB)

(72) Inventor: **Melia, Colin David**
1 Gritley Mews Meadow Way
The Meadows Nottingham(GB)

(72) Inventor: **Lampard, John Francis**
22 Windsor Crescent
Woodthorpe Nottingham(GB)

(74) Representative: **Thacker, Michael Anthony et al,**
THE BOOTS COMPANY PLC Patents Section R4
Pennyfoot Street
Nottingham NG2 3AA(GB)

(54) Sustained-release pharmaceutical formulation containing xanthan gum.

(57) A sustained release pharmaceutical formulation comprising xanthan gum, a pharmaceutically active ingredient for example, ibuprofen or flurbiprofen, and other optional excipients.

BEST AVAILABLE COPY

EP 0 234 670 A2

Therapeutic Agents

This invention relates to controlled release formulations of therapeutic agents and in particular to sustained release formulations.

5 Sustained release formulations containing a pharmacologically active ingredient are employed where it is desired to administer a drug to a patient over a prolonged period without requiring the patient to take repeated doses of the drug at short intervals.

10 Substances which hydrate in an aqueous medium to form a gel are known to be used in combination with a pharmacologically active ingredient to provide a sustained release formulation in a solid dosage form. In such a solid dosage form, particles of the active
15 ingredient are mixed with the hydratable substance. When the solid dosage form comes into contact with an aqueous medium, as is found in the gastro-intestinal tract for example, the hydratable substance swells to form a gel. Commonly the drug is released into the
20 body by a combination of erosion and diffusion mechanisms depending on the nature of the gel formed.

Hydrophilic gums are known hydratable substances which provide controlled release formulations (see for example UK 131869 and US 3065143). However, in order
25 to provide sustained release sufficient to enable once or twice daily administration, the above references disclose that gums, such as galactomannans, sodium alginate, gum karaya, pectin, sodium polypectate and agar, must, in general, comprise a large proportion of
30 the solid dosage form. It should be appreciated that not all gums having hydrophilic properties will be suitable per se to provide sustained release formulations.

Xanthan gum is one of many excipients suggested for use as a gelling or thickening agent in food and pharmaceutical preparations (see Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Edition, vol. 15, p.450). US 4163777 relates to an antacid delivery form which dissolves over a period of up to one hour in the mouth. The formulation requires that the acid neutralization product is presented in a matrix including a sugar or a sugar alcohol; it also includes small proportions of a water insoluble lipid material and a gel-forming swelling agent which are used to produce a lozenge which is adapted to respond to the conditions found in the mouth to release the antacid product slowly. The gel forming, swelling agents used are said to be those pharmaceutically acceptable high molecular weight substances which swell and form a gel upon contact with water, including various gums, polysaccharides, cellulose derivatives and the like. Included among the examples of suitable swelling agents is xanthan gum. Xanthan gum is also known to have a synergistic swelling action in combination with locust bean gum (see for example Kirk-Othmer, 3rd Edition, vol. 15, p.450). This combination is disclosed in UK 2165451 which relates to a tablet adapted to dissolve in the mouth over a period of up to two hours. These tablets require the presence of a very large proportion of monosaccharide or disaccharide (i.e. of the order of 70% or more), but only a very small amount of the xanthan/locust bean gum combination in order to function effectively to satisfy the particular requirements of a buccal tablet.

US 4248858 relates to a 3 component sustained release composition for oral administration. It consists of a compressed core, a seal coating surrounding the core and a sugar coating containing a further dose of active ingredient surrounding the seal-

coated core. The core formulations, in addition to the drug for which sustained release is desired, comprise about 30 to about 72% by weight of the core of a water soluble polymer and a water insoluble polymer mixture.

5 It is proposed that xanthan gum is one of the pharmaceutically acceptable synthetic polymers and natural gums which may be employed as the water soluble polymer and that the water insoluble polymer may be ethylcellulose or a mixture of ethylcellulose with
10 other synthetic polymers.

Unexpectedly, we have now found that xanthan gum itself has advantageous sustained release properties and in particular we have found that, where the sustained release carrier comprises a major proportion
15 of xanthan gum, lower levels of sustained release carrier than heretofore suggested may be incorporated into a sustained release composition to provide a formulation with valuable sustained release properties. In such formulations the active ingredient is released
20 slowly into the body over a prolonged period, and in particular allows once or twice daily administration of a drug to a patient.

Accordingly, the present invention provides a solid sustained release pharmaceutical formulation
25 comprising a compressed mixture of a pharmacologically active ingredient and 7.5 to 28% by weight of the formulation of a sustained release carrier comprising a major proportion of xanthan gum.

Xanthan gum is a high molecular weight natural
30 carbohydrate produced in a pure culture fermentation process by the *xanthomonas campestris* microorganism. In the fermentation process, *xanthomonas campestris* is cultured in a well-aerated medium containing glucose, a suitable nitrogen source, dipotassium hydrogen

phosphate and trace elements. To provide seed for the final fermentation, the microorganism is grown in several stages with associated identification tests prior to introduction into the final fermentation medium. At the conclusion of the fermentation process, xanthan gum is recovered by precipitation in isopropyl alcohol and is then dried and milled.

Xanthan gum is less prone to natural variation, unlike naturally occurring gums, such as may occur with alginates and locust bean gum for example. It is of unvarying chemical structure and has uniform chemical and physical properties.

When the formulation comprising a sustained release carrier comprising a major proportion of xanthan gum, and the pharmacologically active ingredient comes into contact with an aqueous medium, as is found in the gastro-intestinal fluids, the xanthan gum in the portion of the formulation exposed to the aqueous medium hydrates and swells to form a gel. Xanthan gum has a good swelling action on contact with an aqueous medium and overcomes the problems encountered by gums which either do not hydrate rapidly enough or hydrate too rapidly. Gums which do not readily hydrate are generally unable to hold the tablet together as, on exposure to an aqueous medium, the tablet tends to break up before the gel fully hydrates. Gums which hydrate too rapidly generally also break up quickly as the gel formed is usually very weak and is unable to hold the tablet together. The thickness of the gel surrounding the central core of composition is intermediate between that of the thin layer when a hard gel is formed, as formed by hydroxypropylmethylcellulose gels for example, and the thick layer when a soft gel is formed. In addition the nature of the gel formed is such that unlike hard gels it may be readily

deformed, unlike soft gels it is not disrupted by such deformation and in-vivo it may be expected to pass obstructions and not be impeded in the gastro-intestinal tract.

5 There is a graded reduction in the state of
hydration of the xanthan gum in a formulation according
to the invention, such that at the centre of the dose
form a mixture of non-hydrated sustained release
10 carrier comprising a major proportion of xanthan gum,
pharmacologically active ingredient and other optional
pharmaceutically acceptable excipients exists which
will become fully hydrated with time. Unlike many
controlled release solid dosage forms where the release
15 rate decreases as the tablet is worn away, the nature
and thickness of the gel formed in a formulation
according to the invention enables a controlled and
steady release of the drug into the body to occur. It
is believed that erosion plays a part in the release of
20 active ingredient from the solid composition, however,
the gel formed is of sufficient thickness and abrasion
resistance to allow diffusion to be the principle form
by which the active ingredient is released into the
body whether from the intact doseform or from smaller
25 portions of drug containing gel that are eroded from
it. This mechanism of release is advantageous over the
more commonly known predominantly erosion mechanisms as
it leads to a more controlled rate of release of the
active ingredient into the body. In addition, by
30 maintaining a layer of sufficiently constant
proportions, through which diffusion may occur, a
steady release of the medicament is achieved over a
prolonged period of time. Such a formulation provides
sufficient sustained release characteristics to enable
35 a dose to be administered to a patient only once or
twice daily. In addition, the gelling of xanthan gum
is temperature independent; it is also pH independent

and allows the active ingredient to diffuse out of the formulation at a steady rate as the medicament passes through the digestive system, irrespective of the pH. Thus the formulation is adapted to provide sustained
5 release both in the acidic media of the stomach and also in the intestines. It will be realized that the actual rate of release will depend on the pH solubility of the pharmacologically active ingredient. In addition, formulations according to the invention have
10 valuable storage properties. They also have advantageous processing properties and are particularly suitable for formulation into solid dosage forms.

It has been found the use of xanthan gum in the sustained release carrier generally allows a slower
15 release of active ingredient into the body as compared to the use of naturally occurring hydrophilic gums. As a result, this provides the advantage that the proportion of sustained release carrier in the formulation may be reduced compared to most other
20 sustained release formulations, thus enabling the sustained release formulation to be provided in a relatively small solid dosage form, if desired. As the proportion of sustained release carrier in the formulation is increased, the release of the active
25 ingredient from the formulation is slowed. The amount of sustained release carrier employed in a formulation according to the invention is from 7.5 to 28% by weight of the formulation. Advantageously the sustained release carrier comprising a major proportion of
30 xanthan gum comprises 10-25%, particularly 15-20%, by weight of the formulation.

The sustained release carrier is present to allow the release of the pharmacologically active ingredient from the formulation over a period of time greater than
35 that expected from a conventional immediate release

tablet. If desired, a proportion of the xanthan gum may be replaced in the sustained release carrier by one or more additional polymers having sustained release properties. We prefer to use not more than 50% by weight of the sustained release carrier of such other sustained release polymers; thus the sustained release carrier comprises a major proportion of xanthan gum. Examples of polymers having sustained release properties are water swellable polymers e.g. cellulose ethers, locust bean gum, guar gum, carboxyvinyl polymer, agar, acacia gum, sodium alginate or alginic acid, or film-forming polymers e.g. ethyl cellulose, hydroxypropyl methylcellulose phthalate or acrylic resin. Advantageous formulations according to the invention include a sustained release carrier comprising at least 75% by weight xanthan gum. Especially preferred formulations are those in which the sustained release carrier comprises at least 90% by weight xanthan gum.

The pharmacologically active ingredient may be any active ingredient suitable for use in sustained release formulations, especially aspirin and non-steroidal anti-inflammatory agents, in particular arylalkanoic acid, including their salts, esters, anhydrides, and other derivatives. These compounds are also antipyretics and analgesics. Other representative types of orally active medicaments which may be incorporated in the sustained-release formulations according to the invention include antihypertensives and other cardiovascular agents, antiasthmatic agents, sedatives, stimulants, antibiotics, antispasmodics, nutritional agents, hematinics, anthelmintics, expectorants, hormones of various types including adrenocorticosteroids, androgenic steroids, estrogenic steroids, progestational steroids, and anabolic steroids, nonsteroidal counterparts of the foregoing,

psychic energizers and antiviral agents of all of which types numerous specific embodiments are well known and will be both readily apparent and readily available to one skilled in the art. If desired, more than one
5 pharmacologically active ingredient may be employed.

In a preferred formulation according to the invention the pharmacologically active ingredient comprises non-steroidal anti-inflammatory agents, in particular arylalkanoic acids. Particularly suitable
10 active ingredients for a formulation according to the invention are ibuprofen and flurbiprofen and their pharmaceutically acceptable salts. Especially advantageous sustained release properties are obtained when ibuprofen is combined with sustained release
15 carrier comprising a major proportion of xanthan gum in a formulation according to the invention.

In particular, when formulations comprise ibuprofen and a sustained release carrier according to the present invention, the formulations are
20 therapeutically effective and exhibit valuable bioavailability characteristics. Furthermore, the sustained release effect observed when ibuprofen is the pharmacologically active ingredient may occur for as long as 24 hours, or even longer. Such a formulation
25 provides a "once a day" formulation, thus allowing the patient to take only one dose, comprising one or more unit dosage forms, a day in order to achieve a therapeutically effective level of active ingredient.

In a formulation according to the invention the
30 pharmacologically active ingredient is mixed with the sustained release carrier and the mixture is compressed to produce a solid formulation. Preferably the ingredients are mixed to form a uniform dispersion and, for example, particles of the pharmacologically active

ingredient may be in intimate admixture with particles of the sustained release carrier. Conveniently the sustained release carrier and pharmacologically active ingredient are dispersed substantially throughout the whole formulation.

Pharmaceutically acceptable excipients may also be incorporated into the sustained release formulation. Such pharmaceutically acceptable excipients may be added to modify the rate of drug dissolution and/or facilitate the manufacture of suitable dosage forms of the formulation.

For example, release-modifying pharmaceutically acceptable excipients that may be added in appropriate quantities for their particular ability to modify dissolution rates include, for example: stearic acid, metallic stearates, stearyl alcohol, hydrogenated cotton seed oil, polyethyleneglycol grades 4000 and 6000, surfactants such as sodium lauryl sulphate, polysorbates; lactose, sucrose, sodium chloride and tablet disintegrants for example corn starch, sodium starch glycollate, croscarmellose sodium and alginic acid. The quantity of such release-modifying excipient employed depends on the release characteristics required and the nature of the excipient. For a sustained release formulation according to the invention, the level of excipients used is suitably up to 25%, preferably up to 10% and advantageously up to 5% by weight of the total composition. Preferably the level of excipients is from 0.5-8% by weight, especially from 1-5% by weight.

The pharmaceutically acceptable excipients recognised by those skilled in the art, ie. formulation excipients, which may be necessary for the formation of suitable dosage forms include, but are not limited to,

binders for example polyvinylpyrrolidone, gelatin, pregelled starches, microcrystalline cellulose; diluents for example lactose, sodium chloride; dextrins, calcium phosphate, calcium sulphate; lubricants for example stearic acid, magnesium stearate, calcium stearate, Precirol (trade mark) and flow aids for example talc or colloidal silicon dioxide. If necessary, such formulation excipients may be used in large quantities, particularly where the composition comprises a small amount of pharmacologically active ingredient. Preferably up to 50%, suitably up to 30% and especially up to 15% by weight of the composition of these above-mentioned excipients are employed.

15 The ratio of sustained release carrier comprising a major proportion of xanthan gum to pharmacologically active ingredient is preferably in the range 1:20 to 100:1.

20 For dosage forms containing a relatively high dose, in particular greater than 100 mg, of pharmacologically active ingredient, for example, ibuprofen, then the ratio of the sustained release carrier of the present invention to pharmacologically active ingredient may be in the range 1:20 to 1:1, suitably 1:15 to 1:1 parts by weight. More preferred ratios fall within 1:10 to 1:1, and advantageously 1:5 to 1:2 parts by weight of the sustained release carrier to pharmacologically active ingredient.

30 For dosage forms containing a relatively low dose of pharmacologically active ingredient, i.e. less than 100 mg and particularly less than 50 mg, the above ratios may be reversed in order to provide a solid dosage form of a suitable size for administration to a patient, i.e. preferably within the range of ratios

20:1 to 1:1, suitably 15:1 to 1:1, especially 10:1 to 1:1, and advantageously 5:1 to 2:1 parts by weight of sustained release carrier comprising a major proportion of xanthan gum to pharmacologically active ingredient.

- 5 For very low dose pharmacologically active ingredients, i.e. particularly less than 10 mg, the ratio of sustained release carrier to pharmacologically active ingredient may be in the range 100:1 to 1:1, preferably 50:1 to 1:1 parts by weight.

- 10 Preferred formulations according to the invention are obtained when the compositions comprise 75-90% by weight ibuprofen and 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum. Especially advantageous formulations
15 comprise 85-90% by weight ibuprofen and 15-20% by weight of a sustained release carrier comprising a major proportion of xanthan gum.

- Advantageously formulations according to the invention comprise 20-50% by weight flurbiprofen,
20 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum, and 25-70% by weight pharmaceutically acceptable excipients, particularly 30-40% by weight flurbiprofen and 10-20% by weight of a sustained release carrier
25 comprising a major proportion of xanthan gum together with 40-60% by weight of pharmaceutically acceptable excipients.

- The sustained release medicament is provided in solid form, conveniently in a unit dosage form. It may
30 be formed into any desired solid dosage presentation, for example gelatin capsules, tablets, lozenges, suppositories, pessaries or implants. It is preferred to provide the sustained release medicament in a solid unit dosage form for oral administration, especially in

tablet form. Preferably, it is intended to release the pharmacologically active ingredient slowly after ingestion within the body as the formulation progresses along the gastro-intestinal tract. In this regard, the
5 gastro-intestinal tract is considered to be the abdominal portion of the alimentary canal, i.e. the lower end of the oesophagus, the stomach and the intestines.

The solid dosage form of the sustained release
10 medicament may optionally be provided with a coating of any conventional coating material, e.g. a film coating material.

A sustained release formulation according to the invention may be formed into a solid dosage
15 presentation according to conventional processes. The pharmacologically active ingredient and sustained release carrier comprising a major proportion of xanthan gum together with other optional pharmaceutically acceptable excipients are mixed and
20 then compressed to produce a solid formulation. In one such method the pharmacologically active ingredient is mixed with a minor proportion of the sustained release carrier of the present invention to form a dry mixture of powders. The mixture is then granulated using a
25 binder material in a solvent such as an alcoholic solvent e.g. isopropyl alcohol or a mixture of a miscible organic solvent and an aqueous solvent. The wet granular mass is then dried. The other ingredients, including the remainder of the sustained
30 release carrier of the present invention are dry mixed with the granules and compressed into tablets. Alternatively, if the nature of the active ingredient permits, all the ingredients may be dry mixed. For example, a metoclopramide sustained release tablet may
35 be produced by dry mixing together the

pharmacologically active ingredient, sustained release carrier of the present invention and suitable pharmaceutically acceptable tableting excipients to form a homogeneous blend, which is then compressed to
5 give a tablet of the correct weight.

The solid formulations according to the invention should be compressed to a sufficient hardness to prevent the premature ingress of the aqueous medium into the core. In a preferred process, wherein a
10 formulation according to the invention is processed into tablet form, advantageously the hardness of the tablets is of the order of 8-20 kp as determined by a Schleuniger hardness tester.

Subject to the nature of the active ingredient, a
15 formulation according to the invention is suitable for human or veterinary use.

The dosages of a formulation according to the invention correspond to the normal dosages of the particular active ingredient known to the man skilled
20 in the art. The precise amount of drug administered to a patient will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history, among other factors, and always lies within the sound discretion of
25 the administering physician. For guidelines as to a suitable dosage, reference may be made to MIMS and to the Physicians Desk Reference.

As stated above, in a preferred pharmaceutical formulation according to the invention, the
30 pharmacologically active ingredient is ibuprofen. Each dosage form suitably contains from 50 to 1200 mg of ibuprofen, preferably from 200 to 800 mg in one or more unit dosage forms. The daily dosage as employed for

an adult human treatment is generally in the range from 100 to 3200 mg. Flurbiprofen is another pharmacologically active ingredient which may be used with advantage with a sustained release carrier comprising a major proportion of xanthan gum. Suitably the dosage of flurbiprofen is from 10-500 mg per day. Suitably the unit dose compositions of the present invention contain 10-250 mg, especially 25-100 mg of the active ingredient. The daily dosage of the drug is generally in the range 10-500 mg/day, more usually 30-300 mg/day.

A particular advantage of the sustained release formulations of this invention is that high levels of ibuprofen and other suitable drugs can be employed. Thus the present preferred compositions suitably comprise at least 50% by weight of ibuprofen, preferably at least 60-95%, especially from 75-90%.

In particular the provisions of a high dose composition having sustained release properties enables a unit dosage formulation of ibuprofen to be produced which is suitable for once- or twice-a-day administration, preferably once-a-day.

The invention is illustrated by the following non-limitative Examples.

In the Examples xanthan gum is supplied under the trade name Keltrol F by Merck & Co. Inc., Kelco Division; colloidal silicon dioxide is supplied under the trade name Aerosil 200; polyvinylpyrrolidone is supplied under the trade name Plasdone K29-32; carrageenan gum is supplied under the trade name Genuvisco; sodium alginate is supplied under the trade name Manugel; microcrystalline cellulose is supplied under the trade name Avicel PH101.

In each of Examples 1 to 18 T50 is the time taken for 50% of the active ingredient to be released from the tablet; T90 is the time taken for 90% of the active ingredient to be released from the tablet.

- 5 These values were determined graphically. Graphs were plotted of the mean percent release of pharmacologically active ingredient vs time. A best fit line was drawn through these points. The T50 and T90 values were read off from this line.

10 Example 1

Sustained release tablets comprising 800 mg ibuprofen were prepared from the following ingredients:-

	<u>Ingredient</u>	<u>mg/tablet</u>
15	Ibuprofen	800.0
	xanthan gum (Keltrol F)	196.9
	colloidal silicon dioxide (Aerosil 200)	3.1
	polyvinylpyrrolidone (Plasdone K29-32)	25.9
	Stearic acid	10.4

- 20 Ibuprofen and 3% of the xanthan gum were deaggregated through a 6 mesh screen into a blender and the dry powders mixed for three minutes at high speed. A solution of polyvinylpyrrolidone prepared in isopropyl alcohol was added to the mixing powder over a
- 25 30 second period. Further mixing and addition of isopropyl alcohol was carried out to produce suitable granules.

- The wet granular mass was discharged through a 4 mesh screen into the drying bowl of a fluid bed dryer.
- 30 The granules were dried until the moisture level

reached below 1% w/w. The dry granules were forced through a 16 mesh screen, weighed and blended with the remainder of the xanthan gum, together with colloidal silicon dioxide and stearic acid for 30 minutes. The
5 blend was compressed on a tablet machine using pillow shaped tooling to produce tablets containing 800 mg of ibuprofen.

The hardness of tablets was determined on a Schleuniger hardness tester.

10 The release rate was determined using the US Pharmacopoeia, 1985, vol XXI apparatus 2. A single tablet was placed into the dissolution flask containing 900 ml of a buffered solution of desired pH, preheated to $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$. The buffer solution was rotated using
15 paddle stirrers maintained at 100 rpm.

At one hour intervals, a small sample of approximately 2 ml supernatant liquid was withdrawn through a 1.2 μ membrane filter. The solution removed from the flask was analysed for the concentration of
20 medicament released from the tablet. The procedure was continued until at least 90% of the tablet medicament had been released.

In order to correspond with the conditions the tablet is likely to meet in vivo as it passes along the
25 gastro-intestinal tract the following schedule of buffer solution was used. The pH was adjusted with 2M aqueous sodium hydroxide solution.

	<u>Hours</u>	<u>pH</u>
	0	2.5
	1	4.5
	2	4.5
5	3	6.8
	4-24	6.8

The release characteristics of the 800 mg ibuprofen sustained release tablet of this Example are shown in Table 1.

Table 1

	Release Rate (hr)	Cumulative % of active ingredient released
5	1	0.2
	2	1.1
	3	2.5
	4	11.4
10	5	17.7
	6	23.3
	7	29.2
	8	36.5
	9	44.6
15	10	53.1
	11	62.0
	12	69.3
	13	72.5
	14	75.5
20	15	82.0
	16	85.2
	17	87.6
	18	91.5
25	HARDNESS 12-15 kp	
	T50 9.5 hr	
	T90 18 hr	

30 A bioavailability study was conducted in 18 volunteers of the 800 mg sustained-release formulation of this Example compared to two standard Brufen 400 mg tablets. Brufen (Registered Trade Mark) is the

proprietary name for ibuprofen and formulations thereof manufactured by The Boots Company PLC. The bioavailability is measured by the area under the plasma concentration vs time curves and is found to be
5 satisfactory. After compensating for the effects of non-linear protein binding (Lockwood et al (1983) Clin. Pharm. Ther. 34(1)92) the area under the curve of the sustained-release formulation was 85% of that obtained following the immediate release reference formulation.

10 Three hours post-dose the plasma level achieved with the sustained-release formulation was $15\mu\text{g.ml}^{-1}$. Levels then slowly declined to approximately $10\mu\text{g.ml}^{-1}$ at six hours after which ibuprofen concentration again increases to give a second maximum of approximately
15 $15\mu\text{g.ml}^{-1}$. The plasma levels of the formulation according to this Example at 12 and 24 hours post-dose were 15 and $3\mu\text{g.ml}^{-1}$ respectively compared to levels of $1\mu\text{g.ml}^{-1}$ and zero at 12 and 24 hours following the standard immediate release formulation of the Brufen
20 (Registered Trade Mark) tablets.

There was no evidence of dose dumping in the sustained release formulation.

Example 2

Sustained release tablets comprising 600 mg ibuprofen were prepared from the following ingredients:-

5	<u>Ingredient</u>	<u>mg/tablet</u>
	Ibuprofen	600.0
	Xanthan gum (Keltrol F)	61.8
	Hydroxypropylcellulose	76.0
	Carrageenan gum (Genuvisco)	20.5
10	Lactose USP	19.0
	Polyvinylpyrrolidone (Plasdone K29-32)	15.0
	Stearic Acid	8.2

The ibuprofen, hydroxypropylcellulose, polyvinylpyrrolidone and lactose USP were formed into granules by the deaggregation, dry mixing, granulation and drying processes as described in Example 1.

The dry granules were blended with the xanthan gum, carrageenan gum and stearic acid for 30 minutes and compressed on a tablet press using pillow shaped tooling to produce tablets containing 600 mg of ibuprofen. The hardness and the release rate of the 600 mg ibuprofen tablets of this Example were determined as described in Example 1. Table 2 shows the release characteristics of the 600 mg ibuprofen sustained release tablets.

Table 2

	Release Rate (hr)	Cumulative % of active ingredient released
5	1	0.5
	2	2.7
	3	5.2
	4	26.6
10	5	42.0
	6	47.9
	7	53.2
	8	58.1
	9	63.1
15	10	68.1
	11	72.8
	12	76.8
	13	79.8
	14	81.3
20	15	83.8
	16	86.5
	17	90.0
HARDNESS 14-18 kp		
25	T50 6.5 hr	
	T90 17.0 hr	

Example 3

Sustained release tablets comprising 800 mg ibuprofen were prepared from the following ingredients:-

5	<u>Ingredient</u>	<u>mg/tablet</u>
	Ibuprofen	800.0
	Xanthan gum (Keltrol F)	222.2
	Sodium alginate (Manugel)	55.6
	Polyvinylpyrrolidone (Plasdone K29-32)	22.2
10	Stearic Acid	11.1

The ibuprofen, sodium alginate and polyvinylpyrrolidone were formed into granules by the deaggregation, dry mixing, granulation and drying processes described in Example 1.

15 The dry granules were blended with the xanthan gum and stearic acid for 30 minutes and compressed on a tablet press using pillow shaped tooling to produce tablets containing 800 mg of ibuprofen.

20 The hardness and the release rate of the 800 mg ibuprofen tablets of this Example were determined as described in Example 1 to give the results shown in Table 3.

Table 3

	Release Rate (hr)	Cumulative % of active ingredient released
5	1	0.1
	2	0.6
	3	2.0
	4	13.0
10	5	25.6
	6	38.5
	7	51.7
	8	60.4
	9	66.4
15	10	71.7
	11	77.3
	12	81.9
	13	83.9
	14	85.8
20	15	92.1
HARDNESS 10-13 kp		
T50 7 hr		
25	T90 14.7 hr	

Example 4

Sustained release tablets comprising 200 mg
flurbiprofen were prepared from the following
30 ingredients:-

<u>Ingredient</u>	<u>mg/tablet</u>
Flurbiprofen	200.0
Lactose USP	242.4
Xanthan gum (Keltrol F)	112.0
5 Magnesium Stearate	5.6

10 The flurbiprofen, lactose and xanthan gum were formed into granules by the deaggregation, dry mixing, granulation, and drying processes substantially as described in Example 1, but by using purified water as the granulating solvent.

The dry granules were blended with magnesium stearate and compressed on a tablet press to produce tablets containing 200 mg of flurbiprofen.

15 The hardness and release rate of the 200 mg flurbiprofen tablets of this Example were determined as described in Example 1 to give the following results shown in Table 4.

Table 4

	Release Rate (hr)	Cumulative % of active ingredient released
5	1	0.3
	2	0.3
	3	1.22
	4	6.3
10	5	12.87
	6	15.06
	7	20.44
	24	98.3
15	HARDNESS 9-11 kp	
	T50 14 hr	
	T90 23 hr	

20 Example 5

Sustained release tablets comprising 200 mg flurbiprofen were prepared from the following ingredients:-

	<u>Ingredient</u>	<u>mg/tablet</u>
25	Flurbiprofen	200.0
	Lactose USP	298.4
	Xanthan gum (Keltrol F)	56.0
	Magnesium Stearate	5.6

30 The flurbiprofen, lactose and xanthan gum were formed into granules by the deaggregation, dry mixing,

granulation and drying processes substantially as described in Example 1 but by using purified water as the granulating solvent.

5 The dry granules were blended with magnesium stearate and compressed on a tablet press to produce tablets containing 200 mg of flurbiprofen.

10 The hardness and the release rate of the 200 mg flurbiprofen tablets of this Example were determined as described in Example 1 to give the results shown in Table 5.

Table 5

	Release Rate (hr)	Cumulative % of active ingredient released
5	1	0.3
	2	2.0
	3	2.1
	4	19.0
10	5	37.0
	6	62.5
	7	68.5
	8	71.5
	9	74.0
15	10	75.0
	12	81.5
	14	89.5
	16	95.0
20	HARDNESS 9-11 kp	
	T50 5-6 hr	
	T90 14 hr	

25 Examples 6-18 comprise sustained release
formulations produced in a similar manner to that
described in Example 1. Table 6 indicates the
ingredients and their proportion in the formulation.
The amount of each ingredient is shown as a percentage
30 of the weight of the tablet; the percentage of the
sustained release carrier is also shown as a percentage
weight of the total tablet. Table 6 also shows the
hardness and T50 and T90 values for each formulation.

- 28 -

Table 6

Example	6	7	8	9	10
<u>Ibuprofen content</u> <u>(mg) per tablet</u>	<u>800 mg</u>	<u>800 mg</u>	<u>600 mg</u>	<u>600 mg</u>	<u>800 mg</u>
5 Xanthan gum (Keltrol F)	10.0%	15.0%	5.0%	2.5%	7.5%
Carrageenan gum (Genuvisco)	-	-	2.5%	2.5%	-
10 Sodium alginate (Manugel)	-	-	-	-	7.5%
Hydroxypropyl cellulose	-	-	-	-	-
15 Polyvinyl pyrrolidone (Plasdone K29-32)	2.0%	2.0%	2.0%	2.0%	1.0%
Stearic acid	1.0%	1.0%	1.0%	3.0%	1.0%
microcrystalline cellulose (Avicel PH101)	-	-	-	-	-
20 Lactose USP	-	-	5.0%	6.0%	-
SUSTAINED RELEASE CARRIER	10%	15%	7.5%	10%	15%
HARDNESS (kp)	12.2	13.1	-	15.2	10.5
T50 (hr)	6.4	7.8	3.5	4.5	5.7
25 T90 (hr)	19.0	19.0	7.5	10.0	8.5

Table 6 (continued)

Example	11	12	13	14	15
<u>Ibuprofen content</u> <u>(mg) per tablet</u>	<u>800 mg</u>	<u>800 mg</u>	<u>800 mg</u>	<u>800 mg</u>	<u>800 mg</u>
5 Xanthan gum (Keltrol F)	10.0%	13.0%	13.0%	20.0%	23.0%
Carrageenan gum (Genuvisco)	-	-	-	-	-
10 Sodium alginate (Manugel)	5.0%	5.0%	5.0%	5.0%	3.0%
Hydroxypropyl cellulose	-	-	-	-	-
Polyvinyl pyrrolidone (Plasdone K29-32)	2.0%	2.0%	2.0%	2.0%	2.0%
15 Stearic acid	1.0%	1.0%	1.0%	1.0%	1.0%
microcrystalline cellulose (Avicel PH101)	-	2.0%	-	-	-
20 Lactose USP	-	-	-	-	-
SUSTAINED RELEASE CARRIER	15%	18%	18%	25%	26%
HARDNESS (kp)	12.9	11.6	13.9	13.3	14.9
T50 (hr)	7.0	5.0	5.9	7.4	9.0
25 T90 (hr)	9.8	8.6	9.8	11.7	22.5

Example 16

Sustained release tablets containing 40 mg metoclopramide were prepared in a similar manner to that described in Example 1 from the following ingredients:-

<u>Ingredient</u>	<u>% w/w</u>
Metoclopramide Hydrochloride	12.3
Xanthan gum (Keltrol F)	28.0
Microcrystalline cellulose (Avicel PH101)	43.9
10 Polyvinylpyrrolidone (Plasdone K29-32)	2.5
Lactose BP	12.3
Stearic Acid	1.0

The release rate of a proprietary immediate release tablet [Maxolon (Registered Trade Mark) supplied by Beecham Group PLC, Brentford, Middlesex, UK] containing 10 mg metoclopramide was compared to the release rate obtained with the above-described sustained release formulation. The release rate was determined using the US Pharmacopoeia, 1985, vol. XXI apparatus 2. A single tablet was placed into the dissolution flask containing 900 ml of a buffered solution at pH 7.2, preheated to 37°C ± 0.5°C. The buffer solution was rotated using paddle stirrers maintained at 100 rpm. At one hour intervals, a small sample of supernatant liquid was withdrawn through a 1.2µ membrane filter. The solution removed from the flask was analysed for the concentration of medicament released from the tablet. The procedure was continued until at least 90% of the tablet medicament had been released. The results are shown in Table 7 below.

Table 7

Time (min)	% Drug Released from the System	
	Proprietary Immediate Release Tablet	Sustained Release Tablet According to the Invention
5		
5	100	-
10		
10		-
10		-
10		14
10		23
10		37
10		51
15		63
15		67
15		73
15		79
15		85
20		92
20		98
20		
20		
20		
20		
25		
T50	2 min	2.9 hr
T90	4 min	8.7 hr

Example 17

30 Sustained release tablets containing 150 mg
indomethacin were prepared in the same way as described
in Example 1 from the following ingredients:-

	<u>Ingredient</u>	<u>% w/w</u>
	Indomethacin	46.1
	Xanthan gum (Keltrol F)	23.0
	Microcrystalline cellulose (Avicel PH101)	15.0
5	Polyvinylpyrrolidone (Plasdone K29-32)	2.5
	Lactose	12.3
	Stearic Acid	1.0
	Isopropyl alcohol q.s.	

10 The release rate of the above-described sustained release tablet containing 150 mg indomethacin was compared with

- 15 a) a proprietary immediate release tablet
[Indocid (Registered Trade Mark); Thomas Marson Pharmaceutical (Merck Sharpe & Dohme Ltd., Herts., UK)] containing 50 mg indomethacin; and
- 20 b) a proprietary sustained release tablet
[Indocid R (Registered Trade Mark); Thomas Marson Pharmaceutical (Merck Sharpe & Dohme Ltd., Herts., UK)] containing 75 mg indomethacin

The release rates were determined in the same manner as described in Example 16.

The results are shown in Table 8 below.

Table 8

5	Time (min)	% Drug Released from the System		
		(a) Proprietary Immediate Release Tablet	(b) Proprietary Sustained Release Tablet	Sustained Release Tablet According to the Invention
10	5	73	-	-
	10	95	-	-
	15	100	-	-
	20	100	-	-
15	30		66.6	-
	60		90.3	4.0
	120		96.9	6.0
	180			9.0
	240			15.0
20	300			24.0
	360			39.0
	420			59.0
	480			86.0
	540			93.0
25	600			96.0
	720			99.0
	900			100.0
	1200			
30	T50	2.5 min	18 min	6.6 hr
	T90	8.5 min	60 min	8.6 hr

Example 18

35 Sustained release tablets containing 300 mg theophylline were prepared in the same manner as described in Example 1 from the following ingredients:-

	<u>Ingredient</u>	<u>% w/w</u>
	Theophylline BP (anhydrous)	46.1
	Xanthan gum (Keltrol F)	28.0
	Microcrystalline cellulose (Avicel PH101)	10.0
5	Lactose BP	12.3
	Polyvinylpyrrolidone (Plasdone K29-32)	2.5
	Stearic Acid	1.0
	Isopropyl Alcohol	qs
10	The release rate of the above-described sustained release tablet containing 300 mg theophylline was compared with	
15	a) a proprietary immediate release tablet [Tedral (Registered Trade Mark); Parke-Davis, Hants., UK] containing 120 mg theophylline; and	
	b) a proprietary sustained release tablet [Theo-Dur (Registered Trade Mark), Fisons Pharmaceuticals Ltd., Leics., UK] containing 300 mg theophylline.	

20 The release rates were determined in the same manner as described in Example 16.

The results are shown in Table 9 below.

Table 9

% Drug Released from the System				
Time (min)	(a)	(b)	Sustained Release Tablet According to the Invention	
	Proprietary Immediate Release Tablet	Proprietary Sustained Release Tablet		
5				
10				
	5	85.5		
	10	100		
	20			
	30			
15	60	18.7		6.2
	120	29.4		12.3
	180	40.8		17.5
	240	55.3		22.8
	300	77.0		27.9
20	360	90.8		32.4
	420	95.2		36.2
	480	97.6		40.9
	540			45.0
	600			49.8
25	720			57.2
	900			69.2
	1200			91.0
	T50	2 min	3.5 hr	10 hr
30	T90	5 min	6.0 hr	20 hr

Claims

1. A solid sustained release pharmaceutical formulation comprising a compressed mixture of a pharmacologically active ingredient and 7.5 to 28% by weight of the formulation of a sustained release carrier comprising a major proportion of xanthan gum.
2. A formulation according to claim 1 wherein the sustained release carrier comprises at least 75% by weight xanthan gum.
3. A formulation according to either one of claims 1 and 2 wherein the sustained release carrier comprises at least 90% by weight xanthan gum.
4. A formulation according to any one of claims 1 to 3 comprising 10 to 25% by weight of the formulation of a sustained release carrier.
5. A formulation according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 20:1 to 1:20 parts by weight.
6. A formulation according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 1:10 to 1:1.
7. A formulation according to any one of the preceding claims wherein the pharmacologically active ingredient comprises a non-steroidal anti-inflammatory agent.
8. A formulation according to any one of the preceding claims wherein the pharmacologically active

ingredient comprises an arylalkanoic acid or a pharmaceutically acceptable salt thereof.

9. A formulation according to any one of the preceding claims wherein the pharmacologically active
5 ingredient comprises ibuprofen or a pharmaceutically acceptable salt thereof.

10. A formulation according to claim 9 comprising 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.

10 11. A formulation according to either one of claims 9 and 10 comprising 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 75-90% by weight of ibuprofen or a pharmaceutically acceptable salt thereof.

15 12. A formulation according to any one of claims 9 to 11 comprising 10-25% by weight xanthan gum and 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.

20 13. A formulation according to any one of claims 1 to 8 wherein the pharmacologically active ingredient comprises flurbiprofen or a pharmaceutically acceptable salt thereof.

25 14. A formulation according to claim 13 comprising 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 20-50% by weight flurbiprofen or a pharmaceutically acceptable salt thereof.

15. A formulation according to any one of the preceding claims presented in the form of a tablet.

16. A process for the preparation of a formulation according to claim 1 comprising mixing the sustained release carrier comprising a major proportion of xanthan gum with the pharmacologically active ingredient and compressing the mixture to produce a solid formulation.
- 5

Claims for Austria, Greece and Spain

1. A process for the preparation of a solid sustained release pharmaceutical formulation comprising a compressed mixture of a pharmacologically active ingredient and 7.5 to 28% by weight of the formulation of a sustained release carrier comprising a major proportion of xanthan gum comprising mixing the sustained release carrier with the pharmacologically active ingredient and compressing the mixture to produce a solid formulation.
2. A process according to claim 1 wherein the sustained release carrier comprises at least 75% by weight xanthan gum.
3. A process according to either one of claims 1 and 2 wherein the sustained release carrier comprises at least 90% by weight xanthan gum.
4. A process according to any one of claims 1 to 3 wherein the formulation comprises 10-25% by weight of a sustained release carrier.
5. A process according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 20:1 to 1:20 parts by weight.
6. A process according to any one of the preceding claims wherein the ratio of sustained release carrier to pharmacologically active ingredient is in the range 1:10 to 1:1.
7. A process according to any one of the preceding claims wherein the pharmacologically active ingredient comprises a non-steroidal anti-inflammatory agent.

8. A process according to any one of the preceding claims wherein the pharmacologically active ingredient comprises an arylalkanoic acid or a pharmaceutically acceptable salt thereof.

5 9. A process according to any one of the preceding claims wherein the pharmacologically active ingredient comprises ibuprofen or a pharmaceutically acceptable salt thereof.

10 10. A process according to claim 9 wherein the formulation comprises 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.

15 11. A process according to either one of claims 9 and 10 wherein the formulation comprises 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 75-90% by weight of ibuprofen or a pharmaceutically acceptable salt thereof.

20 12. A process according to any one of claims 9 to 11 wherein the formulation comprises 10-25% by weight xanthan gum and 75-90% by weight ibuprofen or a pharmaceutically acceptable salt thereof.

25 13. A process according to any one of claims 1 to 8 wherein the pharmacologically active ingredient comprises flurbiprofen or a pharmaceutically acceptable salt thereof.

30 14. A process according to claim 13 wherein the formulation comprises 10-25% by weight of a sustained release carrier comprising a major proportion of xanthan gum and 20-50% by weight flurbiprofen or a pharmaceutically acceptable salt thereof.

15. A process according to any one of the preceding claims wherein the formulation is presented in the form of a tablet.

⑫ **EUROPEAN PATENT APPLICATION**

⑲ Application number: **87300035.0**

⑤① Int. Cl.³: **A 61 K 9/22**
A 61 K 47/00

⑳ Date of filing: **06.01.87**

③① Priority: **18.01.86 GB 8601204**

④③ Date of publication of application:
02.09.87 Bulletin 87/36

⑥⑥ Date of deferred publication of search report: **13.01.88**

⑧④ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑦① Applicant: **THE BOOTS COMPANY PLC**
1 Thane Road West
Nottingham NG2 3AA(GB)

⑦② Inventor: **Pankhania, Mahendra Govind**
20 Queens Road East
Beeston Nottingham(GB)

⑦② Inventor: **Melia, Colin David**
1 Gritley Mews Meadow Way
The Meadows Nottingham(GB)

⑦② Inventor: **Lampard, John Francis**
22 Windsor Crescent
Woodthorpe Nottingham(GB)

⑦④ Representative: **Thacker, Michael Anthony et al.**
THE BOOTS COMPANY PLC Patents Section R4
Pennyfoot Street
Nottingham NG2 3AA(GB)

⑥④ Sustained-release pharmaceutical formulation containing xanthan gum.

⑥⑦ A sustained release pharmaceutical formulation comprising xanthan gum, a pharmaceutically active ingredient for example, ibuprofen or flurbiprofen, and other optional excipients.



European Patent
Office

EUROPEAN SEARCH REPORT

0234670

Application number

EP 87 30 0035

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Y	GB-A-2 055 577 (AMERICAN HOME PRODUCTS CORP.) * Claims 1,6-11; page 1, lines 104-111; example 1D *	1-7	A 61 K 9/22 A 61 K 47/00
Y,D	US-A-4 163 777 (A.K. MITRA) * Column 2, lines 53-60; column 4, lines 8-16; table 13; claim 1 *	1-7	
Y	EP-A-0 103 995 (CILAG AG) * Page 2, lines 12-17,31,32; claims *	1-7	
Y	FR-A-2 138 492 (CENTRE EUROPEEN DE RECHERCHES MAUVERNAY) * Claims; example 1 *	1-7	
A	GB-A-2 067 072 (THE BOOTS CO.) * Claims 1,6,8 *	1,8-15	A 61 K
E	WO-A-8 705 212 (M. CALANCHI et al.) * Whole document; in particular page 3, lines 19-24; page 6, line 21; examples *	1-16	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 28-10-1987	Examiner GERLI P.F.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO Form 1503 03/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)